



March 2022 Newsletter

2022 “Campaign for Cures” Research Goal, Vaccine Development Update and Request for Support

Dear Friend:

The John Paul II Medical Research Institute’s (JP2MRI’s) 2022 “Campaign for Cures” initiative seeks to raise \$1 million to help advance ethical research in areas of large unmet medical needs. As most people know by now, the current COVID vaccines that are morally tainted with aborted fetal cells have caused significant harm towards religious and personal freedom, causing many to even lose their livelihoods. In 2021, these COVID vaccines generated approximately 50 billion dollars for 4 drug companies. However, vaccines are only the tip of the iceberg when it comes to controversial medicines. The biopharmaceutical industry routinely generates over 100 billion dollars in annual revenue from products and services that use morally-illicit cells. For the public, and particularly for the religious consumer market, this is a staggering problem for which an ethical and parallel economy in biotechnology is desperately needed.

JP2MRI’s next step is to help facilitate the creation of this parallel, but ethical, biotechnology economy by forging collaborations between private businesses and other non-profit organizations and applying innovative science to solve these significant deficiencies. For years, JP2MRI has taken the lead in warning about the ubiquitous use of embryonic stem cell lines and aborted fetal cell lines such as HEK-293 and Per.C6, which are used in the creation of highly profitable drugs. While the Catholic Church has advocated for decades about the need for alternative and ethical human cell lines to produce morally-licit treatments, there has been no concerted effort by the research community until the formation of JP2MRI. Inspired by our late Holy Father, St. Pope John Paul II, JP2MRI is now poised to address this immoral practice and unmet needs by serving as a catalyst for change by utilizing our novel intellectual property and assets. We hope to build on all of our work and use this year’s funds to begin to translate our basic research into eventual clinical trials.

2022 has brought exciting news - on March 8, 2022, the United States Patent and Trade Mark Office (USPTO) issued a patent to Cellular Engineering Technologies (CET), a for-profit and pro-life stem cell company co-founded by JP2MRI’s founder, Dr. Alan Moy, for developing a novel approach in creating ethical and safer induced pluripotent stem cells (iPSC). CET credits much of its success to its collaborative research efforts with JP2MRI. This patent provides a new benchmark in pluripotent stem cell safety, and eliminates the future need for embryonic stem cells (ESC). This milestone completes a longstanding objective that our donors requested in having us find an ethical replacement for ESC. The Institute believes that these ethical stem cells will also be scientifically advantageous when compared to ESC.

For years, our donors urged JP2MRI to create ethical human cell lines that could replace longstanding aborted fetal cells used in the manufacturing of vaccines, cell therapies, gene therapies and biologics. We are pleased to announce that the Institute, with your support, has created a pipeline of immortalized human adult stem cells that are poised to produce non-controversial medicines. A patent will soon be filed by JP2MRI as it relates to our technology and approach. Pro-life Christian scientists in academia, government and industry have been requesting these cell lines for years since the current aborted fetal cell lines have not only posed as a moral dilemma for them, but also threatened their employment status when challenged or refused. We anticipate our cell lines to be commercially released this year.

2022 COVID-19 Vaccine Development Update

Notwithstanding that current COVID-19 vaccines are morally-tainted, real-world experience has also shown that current vaccines suffer from serious adverse reactions; lack robust and durable efficacy; and do not prevent viral transmission. While the pandemic has started to wane, there is general agreement that COVID-19 will transition towards an endemic infection. It is clear that gene therapies that deliver the “spike protein” pose several problems- these subunit vaccines lack durability; cannot prevent viral transmission; induce biological pressure for the virus to mutate and become drug resistant; and, in some cases, increase the severity of an infection. Real world experience has also shown that those who recover from COVID-19 exhibit more robust and durable immunity; protect themselves from severe re-infection; and reduce viral transmission. These observations suggest that a more robust vaccine requires multiple viral antigens and should be nasally delivered. JP2MRI has chosen to devote its research effort on creating a first-in-class attenuated coronavirus vaccine platform that utilizes our ethical cell lines and potentially offers more robust and durable immunity than current gene therapies that require repeated boosters every 6 months. Our objective is to offer a new approach that protects against future national security threats. We have already completed many of the critical elements necessary. Using our ethically derived human cell lines, the Institute has created a pipeline of live attenuated vaccine candidates. Also, we have created the building blocks to produce viral-like particles (VLP) of COVID-19 that are devoid of viral genetic material, which offer a layer of safety for immunocompromised individuals. JP2MRI will soon initiate a research project with the University of Iowa to determine if our immortalized human cells can ultimately produce the vaccine and show proof of

concept that it offers protection and reduces viral transmission in animal subjects. This work comes with a significant price tag and the timeline for how quickly the work begins will depend on our funding level and solving technical challenges along the way. If these preliminary studies are successful, the results will be leveraged to raise the necessary capital and funding to bring a vaccine to clinical trial. However, it is important to recognize that vaccine development is an arduous process that usually takes years to complete in order to gather sufficient data to demonstrate efficacy and safety - a process largely neglected during "Operation Warp Speed". If our research is successful, the platform will also be poised to likely improve flu vaccines and help lead to the creation of ethical childhood vaccines.

The Institute Continues to Develop Ethical Therapies for Large Unmet Needs

JP2MRI now has access to a broad pipeline of ethical technologies to produce new medicines that do not require aborted fetal cells. We have also initiated collaborations with biotechnology companies to deploy our immortalized human cells to develop recombinant proteins and gene therapies that can be used for treating common and rare diseases, as well as cancers. Additionally, we continue to develop a pipeline of stem cell therapies for treating juvenile diabetes and neurodegenerative diseases. Stem cell therapies are divided into therapies that act either through cell protection/repair or cell replacement. We are the only non-profit organization in the world that has capabilities to produce both categories of cell therapy. The Institute is developing universal cell therapies for neurological conditions such as stroke, traumatic brain injury, cerebellar degeneration and Parkinson's disease. If the research and funding continue to grow, it is anticipated that clinical trials could be started in as little as five years. This year, the Institute is working to establish clinical research sites with Catholic healthcare systems in other states across the United States.

Request for Support

Your continued financial support will ensure that immoral cell lines are permanently replaced by ethical options that are safer and more effective and which will lead to new treatments and cures. JP2MRI provides regular updates on our research progress on our website (www.jp2mri.org), on Facebook, on Rumble.com and on Gab.com. Please follow our efforts and make a meaningful donation to help support this important mission. Thank you very much.

Kind regards and God Bless,



Jay M. Kamath, J.D. / CEO
John Paul II Medical Research Institute

2500 Crosspark Rd., Suite W230
Coralville, IA 52241
(office): 319-688-7367
(fax): 319-887-2870
www.jp2mri.org

John Paul II Medical Research Institute Annual Support

\$500 \$400 \$300 \$250 \$100 \$75 \$50 \$25 \$___

Please provide phone and email address for the following:

- I would like to make a monthly contribution.
- I would like to sign up on the Patient Registry.
- I would like to sign up on the Physician Registry.
- I am a first-time donor: __ Yes __ No
- I would prefer to receive the newsletters by email.
- I / We have moved since the last newsletter. Our new address is _____.

Phone: _____ Email: _____

<<first>> <<last>>
<<address>>
<<city>>, <<st>>, <<zip>>

Please make checks out to: JP2MRI

- Check
- Cash
- PayPal (Go to: www.jp2mri.org)

Date: _____

Send to:
JP2MRI
2500 Crosspark Rd.
Suite W230
Coralville, IA 52241